1131 - 1140 of 7939 Results
Title
Year
-
RESTRICTEDTitle: LRRK2-targeted Parkinson disease drug advances into phase IIIJournal Name: Nature Reviews Drug DiscoveryPublisher: Springer Science and Business Media LLCVol: 22Issue #: 1Start Page: 3End Page: 5Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1038/d41573-022-00212-0Citation Count: 8
- Predictive modelling of Parkinson’s disease progression based on RNA-Sequence with densely connected deep recurrent neural networks2022OPENTitle: Predictive modelling of Parkinson’s disease progression based on RNA-Sequence with densely connected deep recurrent neural networksJournal Name: Scientific ReportsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41598-022-25454-1Best OA location URL: https://www.nature.com/articles/s41598-022-25454-1.pdfCitation Count: 3
-
OPENTitle: The genetic regulation of protein expression in cerebrospinal fluidJournal Name: EMBO Molecular MedicinePublisher: Springer Science and Business Media LLCVol: 15Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.15252/emmm.202216359Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202216359Citation Count: 21
- Video-Based Facial Movement Analysis in the Assessment of Bulbar Amyotrophic Lateral Sclerosis: Clinical Validation2022OPENTitle: Video-Based Facial Movement Analysis in the Assessment of Bulbar Amyotrophic Lateral Sclerosis: Clinical ValidationJournal Name: Journal of Speech, Language, and Hearing ResearchPublisher: American Speech Language Hearing AssociationVol: 65Issue #: 12Start Page: 4667End Page: 4678Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1044/2022_jslhr-22-00072Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940890Citation Count: 11
- Chemosensory Dysfunction 3-Months After COVID-19, Medications and Factors Associated with Complete Recovery2022OPENTitle: Chemosensory Dysfunction 3-Months After COVID-19, Medications and Factors Associated with Complete RecoveryJournal Name: Annals of Otology, Rhinology & LaryngologyPublisher: SAGE PublicationsVol: 132Issue #: 10Start Page: 1177End Page: 1185Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1177/00034894221138485Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742352Citation Count: 2
- It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum2022OPENTitle: It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid SumJournal Name: Movement DisordersPublisher: WileyVol: 38Issue #: 2Start Page: 342End Page: 347Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.29279Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974855Citation Count: 9
-
OPENTitle: Tailoring Motor Fluctuation Treatment: Beyond Levodopa Dose AdjustmentJournal Name: European Medical JournalPublisher: European Medical GroupVol:Issue #:Start Page: 20End Page: 27Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.33590/emj/10022165Best OA location URL: https://www.emjreviews.com/wp-content/uploads/2022/12/Tailoring-Motor-Fluctuation-Treatment-Beyond-Levodopa-Dose-Adjustment-1.pdfCitation Count: 0
- Brain vitamin D forms, cognitive decline, and neuropathology in community‐dwelling older adults2022OPENTitle: Brain vitamin D forms, cognitive decline, and neuropathology in community‐dwelling older adultsJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 19Issue #: 6Start Page: 2389End Page: 2396Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/alz.12836Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.12836Citation Count: 14
- Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease2022RESTRICTEDTitle: Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s DiseaseJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 65Issue #: 24Start Page: 16801End Page: 16817Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acs.jmedchem.2c01605Citation Count: 10
-
OPENTitle: Spectrum of Pediatric to Early Adulthood POLR3A‐Associated Movement DisordersJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 10Issue #: 2Start Page: 316End Page: 322Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13635Citation Count: 2